Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multi-cohort study of daratumumab-containing therapy in light-chain amyloidosis
CTR20222330Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in light-chain amyloidosis, sponsored by Janssen Pharmaceutical. Started Jan 2023; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on CTR20222330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222330.